Vaccine Phase 3 tests in UAE and Russian Federation promising

Remigio Civitarese
Luglio 20, 2020

Clinical trials of a Russia COVID-19 vaccine developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology jointly with the Russian Defence Ministry are wrapping up at the Burdenko Main Military Clinical Hospital. "We are not randomizing".

"We have also reviewed the headway of Sinovac's COVID-19 vaccine development process.we have found they made potential advancements though the trial is still underway in China", he said. "Healthy volunteers having no comorbid conditions and without a history of COVID-19, aged more than 18 years and less than 55 years, would be eligible to participate in the randomised, double-blind, placebo-controlled clinical trial", Dr Sanjay Rai, Professor at the Centre for Community Medicine at AIIMS said. It will involve a total sample size of 1,125 healthy volunteers in two phases (phase 1 and 2), with 375 in phase-1 involving age groups of 18-55, and 750 volunteers in the age group 12-65 in the phase-2 study.

The AIIMS Ethics Committee gave its nod for a human clinical trial to begin from today. The results are promising because separate studies have indicated that antibodies may fade away within months while T-cells can stay in circulation for years.

AIIMS has also set up an email address and a phone number where people can register to volunteer for the trial.

Abu Dhabi and Al Ain are home to the world's first World Health Organisation-enlisted Phase-III trial, which is the final step before a vaccine is approved for use among the public.

Others like Mynvax and Biological E are also working to develop vaccines for Covid-19.

'As part of our commitment - and should the vaccine prove successful - we have secured 100 million vials that will be available to Queensland, Australia, New Zealand and our Pacific neighbours'. "They will be kept under observation for almost 150 days", added Rai.

The company stated that it is looking to complete clinical trials of its coronavirus vaccine candidate ZyCoV-D in 7 months.

The human trials of Covaxin has begun at the All India Institute of Medical Sciences, Patna. "There were no adverse effects", he said. The drug regulatory body allowed the pharma company to conduct phase I and phase II clinical trials. The same mechanism is being used for the Covid vaccine, substituting the MERS genetic material with the spike protein of SARS-CoV-2 virus.

The drug manufacturer said that the vaccine has been developed in a high containment facility in Hyderabad.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE